Sano Healthcare (688108.SH) has increased ahead of schedule. The net profit for the first half year is expected to be 50.33 million yuan, an increase of 263.66% over the previous year

According to Zhitong Finance App News, Sano Healthcare (688108.SH) released its 2026 semi-annual performance forecast. The company expects to achieve net profit attributable to shareholders of listed companies of 50.33 million yuan in the semi-annual year of 2026, an increase of 263.66% over the previous year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss is expected to be 48.71 million yuan, an increase of 510.40% over the previous year.

In the first half of 2026, the company's performance is expected to increase compared to the same period last year, mainly due to the continued steady volume of products in the coronary business segment and a significant increase in new product sales in the neurological business segment, which is expected to increase revenue by 26.68% year on year. At the same time, operating costs are expected to increase relatively little, and the cost control effect is obvious; sales expenses are expected to be basically the same as the same period last year, and R&D expenses are expected to decline. Combined with the combined effects of factors such as an increase in management expenses and asset impairment losses, it is expected to jointly drive net profit attributable to shareholders of listed companies to achieve a significant year-on-year increase in the current period.